JP2018536671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536671A5 JP2018536671A5 JP2018529006A JP2018529006A JP2018536671A5 JP 2018536671 A5 JP2018536671 A5 JP 2018536671A5 JP 2018529006 A JP2018529006 A JP 2018529006A JP 2018529006 A JP2018529006 A JP 2018529006A JP 2018536671 A5 JP2018536671 A5 JP 2018536671A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- azabicyclo
- octane
- amine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-methyl-1,2,4-thiadiazol-5-yl Chemical group 0.000 claims 104
- 229910052736 halogen Inorganic materials 0.000 claims 55
- 150000002367 halogens Chemical group 0.000 claims 55
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 230000003287 optical effect Effects 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 8
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 7
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 6
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 5
- 201000010374 Down Syndrome Diseases 0.000 claims 5
- 206010044688 Trisomy 21 Diseases 0.000 claims 5
- 206010008118 cerebral infarction Diseases 0.000 claims 5
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GLAYEAGOETWDPL-UHFFFAOYSA-N 1H-triazolo[1,5-a]pyrazin-2-amine Chemical compound N1N(C=C2N1C=CN=C2)N GLAYEAGOETWDPL-UHFFFAOYSA-N 0.000 claims 1
- QGCRJRVFQZXCAZ-UHFFFAOYSA-N 1h-triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CC2=CN(N)NN21 QGCRJRVFQZXCAZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 claims 1
- WOTIUKDGJBXFLG-UHFFFAOYSA-N 3-methyl-1,2-thiazole Chemical compound CC=1C=CSN=1 WOTIUKDGJBXFLG-UHFFFAOYSA-N 0.000 claims 1
- WRTFLEDDMKKOTH-UHFFFAOYSA-N C1C=2N(C=CN1N)C=CC2 Chemical compound C1C=2N(C=CN1N)C=CC2 WRTFLEDDMKKOTH-UHFFFAOYSA-N 0.000 claims 1
- PHTMVIAGTMTVSK-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CN2N=C(N)N=C21 PHTMVIAGTMTVSK-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 C[C@](C(CC1)C2)([C@]1(*)C*2C1=N*C(C)=C1)I Chemical compound C[C@](C(CC1)C2)([C@]1(*)C*2C1=N*C(C)=C1)I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199260 | 2015-12-10 | ||
| EP15199260.9 | 2015-12-10 | ||
| PCT/EP2016/079816 WO2017097728A1 (en) | 2015-12-10 | 2016-12-06 | Bridged piperidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536671A JP2018536671A (ja) | 2018-12-13 |
| JP2018536671A5 true JP2018536671A5 (enExample) | 2019-12-12 |
| JP6872550B2 JP6872550B2 (ja) | 2021-05-19 |
Family
ID=54848457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529006A Active JP6872550B2 (ja) | 2015-12-10 | 2016-12-06 | 架橋されたピペリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10562903B2 (enExample) |
| EP (1) | EP3386978B1 (enExample) |
| JP (1) | JP6872550B2 (enExample) |
| CN (1) | CN108137579B (enExample) |
| AR (1) | AR107010A1 (enExample) |
| TW (1) | TWI629278B (enExample) |
| WO (1) | WO2017097728A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100506T1 (it) | 2015-10-02 | 2021-11-12 | Hoffmann La Roche | Anticorpi bispecifici specifici per pd1 e tim3 |
| CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| EP3475279B1 (en) * | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines as gamma-secretase modulators |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3535266B1 (en) * | 2016-11-01 | 2021-12-29 | F. Hoffmann-La Roche AG | Bicyclic heteroaryl derivatives |
| KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| PL3606955T3 (pl) | 2017-04-05 | 2025-02-24 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3 |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| WO2020048904A1 (en) | 2018-09-03 | 2020-03-12 | F. Hoffmann-La Roche Ag | Bicyclic heteroaryl derivatives |
| SI3894411T1 (sl) * | 2018-12-13 | 2024-10-30 | F. Hoffmann - La Roche Ag | Derivati 7-fenoksi-N-(3-azabiciklo(3.2.1)oktan-8-il)-6,7-dihidro-5H- pirolo(1,2-b)(1,2,4)triazol-2-amina in sorodne spojine kot modulatorji gama-sekretaze za zdravljenje Alzheimerjeve bolezni |
| JP2022515610A (ja) | 2018-12-27 | 2022-02-21 | エフ．ホフマン－ラ ロシュ アーゲー | ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| WO2022238816A1 (en) * | 2021-05-14 | 2022-11-17 | Bm Pharma Consulting Pty. Ltd | Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| KR20060127909A (ko) | 2003-12-24 | 2006-12-13 | 비오타 사이언티픽 매니지먼트 피티와이 엘티디 | 호흡기 다핵체 바이러스 감염 치료용 다환 물질 |
| BRPI0616667B1 (pt) * | 2005-10-06 | 2017-07-18 | Nippon Soda Co. , Ltd. | Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| JP2011529722A (ja) | 2008-08-14 | 2011-12-15 | カーディアック ペースメイカーズ， インコーポレイテッド | 音響通信リンクの性能評価および適合 |
| US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| USRE47689E1 (en) | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ES2733644T3 (es) | 2012-01-26 | 2019-12-02 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| WO2014012050A2 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| WO2014184163A1 (en) | 2013-05-14 | 2014-11-20 | F. Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
| RU2673542C2 (ru) | 2013-06-25 | 2018-11-28 | Ф. Хоффманн-Ля Рош Аг | Соединения для лечения спинальной мышечной атрофии |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| DK3143025T3 (da) | 2014-05-15 | 2019-12-09 | Hoffmann La Roche | Forbindelser til behandling af spinal muskelatrofi |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
-
2016
- 2016-12-06 EP EP16805853.5A patent/EP3386978B1/en active Active
- 2016-12-06 CN CN201680057010.6A patent/CN108137579B/zh active Active
- 2016-12-06 WO PCT/EP2016/079816 patent/WO2017097728A1/en not_active Ceased
- 2016-12-06 JP JP2018529006A patent/JP6872550B2/ja active Active
- 2016-12-07 AR ARP160103753A patent/AR107010A1/es unknown
- 2016-12-09 TW TW105140951A patent/TWI629278B/zh not_active IP Right Cessation
-
2018
- 2018-06-08 US US16/004,145 patent/US10562903B2/en active Active
-
2020
- 2020-02-13 US US16/790,629 patent/US20200291034A1/en not_active Abandoned